How This Actually Works, Step by Step

You do not just fly to Shanghai and get SIRT the following week. The sequence matters. Here is the real pathway, based on cases we have coordinated.

Step 1: You send your existing records. We need recent contrast-enhanced CT or MRI (within 4 weeks), liver function tests, tumor marker levels, and your full treatment history. If you have had prior TACE, resection, or systemic therapy, those details change the SIRT planning significantly. Your records get professionally translated into clinical Chinese—this is not Google Translate work. Terminology errors here can derail a treatment plan.

Step 2: A liver cancer specialist reviews your case. This is not a chatbot triage. An interventional radiologist or nuclear medicine physician at a major Chinese liver cancer center evaluates whether you are actually a SIRT candidate. They look at tumor burden, portal vein involvement, lung shunt fraction risk, and liver reserve. About 30% of patients who think they want SIRT get redirected to TACE or systemic therapy instead—because the mapping angiography shows contraindications.

Step 3: You get a written second opinion. This document spells out candidacy, recommended activity dose, number of treatment sessions, expected hospitalization duration, and a preliminary cost range. It also flags any missing diagnostics. You can take this opinion back to your home oncologist. The fee for this written analysis typically runs $300–500, and it is fully credited if you proceed to treatment coordination.

Step 4: You decide, then we coordinate the treatment slot. Once you commit, the hospital’s international department reserves a treatment window. This is where the book SIRT liver cancer treatment China package search query meets reality—there is no “package” you can buy online. Each case requires individualized workup: a planning angiography with technetium-99m MAA to map lung shunting, dosimetry calculations, and the actual Y-90 administration typically done in a dedicated interventional radiology suite.

Step 5: You travel, undergo the mapping study, then the treatment. The workup angiography and the Y-90 delivery are usually separated by 7–10 days. You are in China for roughly 2–3 weeks total. After the procedure, you stay in the hospital for observation—typically 24–48 hours—then recover at your accommodation with follow-up imaging scheduled before departure.

How Does Yttrium-90 SIRT Work for Liver Cancer

The core question every patient asks. The mechanism is elegant but unforgiving if done wrong.

SIRT delivers radioactive yttrium-90 microspheres directly into the hepatic artery branches that feed liver tumors. Normal liver tissue draws most of its blood from the portal vein. Liver tumors—both primary hepatocellular carcinoma and metastases from colorectal, neuroendocrine, or breast primaries—draw roughly 80–90% of their blood supply from the hepatic artery. This is the physiological loophole SIRT exploits.

An interventional radiologist threads a microcatheter through the femoral artery up into the liver’s arterial tree. They inject millions of tiny resin or glass beads, each loaded with Y-90, a pure beta emitter. The beads lodge in the tumor’s capillary bed and deliver a concentrated radiation dose—typically 100–150 Gy to the tumor—while largely sparing the surrounding functional liver. The radiation penetrates only about 2.5 mm in tissue. After roughly two weeks, the Y-90 decays completely to stable zirconium-90.

This is not a cure for most patients. But it can shrink tumors enough to bridge someone to resection, downstage a patient to transplant eligibility, or simply extend survival with preserved quality of life when sorafenib or lenvatinib have failed. The SARAH and SIRveNIB trials showed SIRT with resin microspheres had comparable overall survival to sorafenib in advanced HCC, with a markedly better side-effect profile. The more recent DOSISPHERE trial demonstrated that personalized dosimetry—delivering at least 205 Gy to the tumor—significantly improved overall survival compared to standard dosimetry.

That dosimetry point matters enormously when evaluating a hospital. Not all centers perform rigorous, personalized dose calculation. Some use a simplified body-surface-area method. The centers we work with use partition-model dosimetry based on the MAA SPECT/CT scan. This is the difference between a precisely targeted therapy and a rough approximation.

Yttrium-90 SIRT Liver Cancer Cost China: Real Numbers

Let’s address the search query directly. The yttrium-90 SIRT liver cancer cost China question has no single answer—but we can give you the real ranges, not marketing estimates.

These are treatment costs only—the hospital bill. They do not include flights, accommodation, visa fees, or coordination services. And they vary significantly by hospital tier. A top-ranked liver cancer center in Shanghai or Beijing charges toward the higher end. A strong provincial cancer hospital may come in 20–30% lower. The selective internal radiation therapy Shanghai price tends to sit at the upper bound because Shanghai hosts several of China’s highest-volume liver centers, including Zhongshan Hospital and Shanghai Cancer Center.

One session often suffices for a single lobe. Bilobar disease may require two separate sessions spaced 4–6 weeks apart, doubling the microsphere cost. Some patients also need repeat SIRT if new lesions develop. These are the variables that make any fixed “package price” misleading.

Also worth noting: China’s prices for the Y-90 microspheres themselves are not dramatically lower than Western prices—the spheres are imported from Sirtex (now part of CDL Nuclear Technologies) or Boston Scientific’s TheraSphere line. The savings come from hospital procedural fees, angiography suite costs, and shorter inpatient stays. A US hospital might keep you for 3–5 days post-procedure. In China, 24–48 hours is standard for uncomplicated cases.

A Realistic Timeline

Everyone wants to know how fast they can get treated. The honest answer includes the waiting nobody talks about.

Total time from first contact to walking out of the hospital post-treatment: roughly 8–12 weeks for most patients. The fastest we have seen is 6 weeks. The longest was 16 weeks, held up by a home-country biopsy that needed re-reading. Plan for 12 weeks and be pleasantly surprised if it moves faster.

What Can Go Wrong—and What Happens Then

We lose trust the moment we pretend everything always works perfectly. It does not. Here are the real failure modes for international SIRT patients in China, and the actual recourse for each.

Lung shunt fraction too high. The MAA scan shows more than 20% of the injected particles shunting to the lungs. This is the most common reason a planned SIRT gets canceled or dose-reduced. If the shunt fraction is borderline (15–20%), the dose gets reduced proportionally. If it exceeds 20%, the interventional radiologist may recommend TACE instead—or may attempt coil embolization of the shunting vessels and re-map. You are not stranded. You have a backup plan discussed before you ever board a plane.

Extrahepatic deposition risk. The planning angiogram reveals that some tumor-feeding arteries also supply the stomach, duodenum, or gallbladder. This is dangerous—Y-90 in the wrong place causes radiation gastritis or ulcers that are notoriously difficult to heal. The IR team can often coil-embolize these collateral vessels to redirect flow. If they cannot safely do so, SIRT is contraindicated. This happens in roughly 5–10% of cases. The mapping study is not a formality; it is the gatekeeper.

Post-embolization syndrome worse than expected. Most patients get fatigue and mild pain. A minority get severe nausea, fever spiking to 39°C, and debilitating fatigue lasting 10–14 days. Chinese hospitals manage this aggressively with IV fluids, antiemetics, and corticosteroids. You stay admitted longer—typically 4–5 days instead of 1–2. The hospital adjusts your discharge date. Your travel insurance or coordination service handles the accommodation changes.

Treatment does not work. SIRT is not a guaranteed response. About 20–25% of patients show minimal tumor shrinkage on 3-month follow-up imaging. This is not a failure of the Chinese hospital—it reflects the biological reality of advanced liver cancer. If SIRT does not achieve the desired response, the same Chinese oncology team can pivot to alternative locoregional therapies or systemic options. You have not burned a bridge; you have established a relationship with a major liver center that can continue managing your case remotely.

Visa delay or denial. Rare with proper documentation, but it happens. The S2 visa requires a hospital invitation letter specifying the treatment purpose and duration. If an embassy officer is unfamiliar with medical S2 applications, processing can stall. We have seen this twice in the past year—both resolved by resubmitting with additional supporting letters. The solution is to apply early and let us handle the documentation packet. We have done this hundreds of times.

Best Hospital for SIRT Treatment in China: How to Evaluate

Rankings matter less than case volume and dosimetry protocol. The best hospital for SIRT treatment in China for your specific tumor biology may not be the one with the most famous name.

China has roughly 40 centers performing Y-90 SIRT regularly. The top-tier liver centers perform 100–200 SIRT procedures annually. Mid-tier centers might do 30–50. The difference shows up in the interventional radiology team’s ability to handle complex vascular anatomy—replaced hepatic arteries, parasitized extrahepatic feeders, tricky catheter positions.

When evaluating a Chinese hospital for SIRT, ask these specific questions:

• How many Y-90 procedures did your IR team perform last year? Look for centers doing at least 80–100 annually. This is not snobbery; it is about the team’s comfort with anatomical variants.
• What dosimetry method do you use? The answer should be “partition model based on MAA SPECT/CT” or “personalized dosimetry.” If they say “body surface area method,” look elsewhere. BSA-based dosing is outdated and associated with lower tumor response rates.
• Do you use resin or glass microspheres, and why? Both are valid. Glass (TheraSphere) delivers higher specific activity per sphere. Resin (SIR-Spheres) delivers more spheres with lower activity each, which some argue provides more uniform tumor coverage. The right answer is “we use both and select based on your tumor characteristics and vascular pattern.”
• What is your lung shunt fraction cutoff for proceeding? 20% is standard. Some aggressive centers push to 25% with dose reduction. Others play it safer at 15%. This tells you about their risk tolerance.

Shanghai and Beijing house the highest-volume centers. Zhongshan Hospital affiliated with Fudan University runs one of the world’s largest liver cancer programs, with a dedicated interventional radiology team performing SIRT alongside TACE and ablation daily. The institution’s liver surgery and interventional volumes are staggering—but that also means the international patient coordination can feel factory-like if you do not have a dedicated liaison. Other strong programs exist at Peking University Cancer Hospital in Beijing and West China Hospital in Chengdu. You can explore our full database of ranked oncology departments on our specialty pages.

For patients specifically searching for selective internal radiation therapy Shanghai price information, Shanghai’s concentration of top liver centers means competitive pricing and high expertise. But it also means higher accommodation costs and a more expensive city for a multi-week stay. Chengdu or Guangzhou may offer comparable medical quality at lower total out-of-pocket cost for the travel portion.

Is Yttrium-90 Radiation Therapy Safe for Liver Metastases

The is yttrium-90 radiation therapy safe for liver metastases question deserves a nuanced answer. The short version: yes, with the right patient selection and dosimetry. The real version matters more.

SIRT is approved and widely used for liver-dominant metastatic colorectal cancer. The SIRFLOX trial showed that adding SIRT to first-line FOLFOX chemotherapy significantly improved liver-specific progression-free survival, though overall survival was not statistically different. For neuroendocrine tumor liver metastases, SIRT achieves impressive response rates—often 50–70% partial response by RECIST criteria—and durable symptom control for patients with carcinoid syndrome.

The safety profile depends heavily on liver function at baseline. Patients with Child-Pugh B or C cirrhosis face significantly higher risks of radiation-induced liver disease (RILD), a potentially fatal complication. Most experienced centers restrict SIRT to Child-Pugh A patients, or carefully selected Child-Pugh B7 patients with small treatment volumes. Total bilirubin above 2.0 mg/dL is generally a contraindication.

Another safety consideration: prior systemic therapy with VEGF inhibitors like bevacizumab can impair hepatic artery healing after SIRT. Most protocols require a 4–6 week washout period before the mapping angiography. Your Chinese interventional radiologist will review your full drug history and coordinate timing with your home oncologist.

Radiation cholecystitis, gastrointestinal ulceration from stray microspheres, and biliary complications occur in roughly 2–5% of cases across large series. These numbers come from experienced centers with rigorous workup protocols. The safety of SIRT is not inherent to the technology—it is earned through meticulous mapping and conservative patient selection.

Practical Considerations: Records, Visa, Payment, and Follow-Up

Beyond the medicine, the logistics determine whether your treatment experience is smooth or stressful.

Medical records. You need DICOM-format imaging on a CD or uploaded to a secure portal, not JPEG screenshots. You need recent labs—within 2 weeks for liver function, within 4 weeks for tumor markers. You need a summary letter from your treating oncologist, in English, stating the diagnosis, prior treatments, and current clinical question. Professional translation into Chinese is non-negotiable. Machine translation of “portal vein tumor thrombus” can come out as something unrecognizable to a Chinese radiologist.

Visa. You apply for an S2 visa, category “private affairs,” with the purpose stated as medical treatment. The hospital provides an official invitation letter with its chop (seal) and registration number. Your accompanying family member applies for their own S2. Processing times vary by Chinese embassy—check your local consulate’s current timeline. We handle the invitation letter coordination as part of our service. The S2 visa typically allows a 60–90 day stay, which covers the treatment and initial recovery period comfortably.

Payment. Chinese public hospitals require upfront payment. You deposit an estimated amount at the international patient center upon registration, and the hospital draws against it for each procedure, lab test, and medication. Any surplus gets refunded at discharge. Credit cards are accepted at major international departments, but wire transfers are more reliable for large amounts. The hospital issues a detailed invoice suitable for insurance reimbursement. Private international hospitals like United Family or Jiahui may offer direct billing with certain global insurers—check your policy.

Follow-up at home. Your Chinese IR team provides a full treatment report in English: administered activity, treated segments, dosimetry calculations, post-treatment imaging findings, and recommended follow-up schedule. You take this to your home oncologist. The Chinese team typically requests follow-up imaging at 3 months and remains available for email consultation. This continuity matters—if you need a second SIRT session for the contralateral lobe, the same team already knows your vascular anatomy.

For broader context on navigating China’s hospital system as an international patient, our top hospitals database provides detailed profiles of ranked institutions across 37 cities.

Frequently Asked Questions